From Diabetes Device to CGM Weight Loss Companion
Continuous glucose monitors, or CGMs, are wearable sensors that track glucose levels in real time, and they are rapidly moving from a niche diabetes tool to a mainstream companion for weight management, especially as GLP-1 medications change how people lose and maintain weight. Traditionally, CGMs served people with diabetes who needed tight glucose control. Now, a rising class of GLP-1 wearables is reframing glucose monitoring as a way to understand how food, sleep and activity affect metabolism for anyone concerned with weight. Weight-loss drugs such as Ozempic and Wegovy have lowered A1C levels for many users and drawn more people into fitness settings, but long-term maintenance remains unsolved once prescriptions stop. In that gap, CGM weight loss services promise data-driven feedback on everyday choices, aiming to help users build habits that outlast medication.
Signos Bets on GLP-1 Users With New Funding and AI Coaching
Signos, maker of an FDA-cleared over-the-counter continuous glucose monitor for weight management, has secured USD 20 million (approx. RM92,000,000) in new funding from a cross-industry group that includes Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama via 450 Ventures. This round follows a previous USD 20 million (approx. RM92,000,000) Series B in 2023 and comes as the company reports tenfold growth over the past six months alongside rising demand for CGM weight loss tools. Signos is building an AI coaching layer that interprets glucose data in real time, offering metabolic guidance, gamified features and a proprietary “Weight Loss Signal” to translate readings into actions. The company argues that GLP-1 drugs blunt hunger but do not teach people how to eat afterward, so its system highlights which foods spike glucose and which meals keep levels within a healthier range.
Beyond Direct-to-Consumer: Health Plans and Pharma Enter the Picture
The latest investment in Signos signals a shift for continuous glucose monitor programs from direct-to-consumer apps toward deeper ties with health plans and pharmaceutical companies. Having a health insurer in its investor group hints that CGM weight loss offerings could become part of covered metabolic care, especially for people starting or tapering off GLP-1 drugs. For payers and drugmakers, CGM data can serve as a companion layer that tracks how people respond to diet and lifestyle changes while on medication, and how they fare once dosing changes. Signos’ CGM will also feature on Dexcom’s consumer website, Stelo.com, placing it alongside a prominent glucose monitoring brand and expanding access beyond its own platform. These moves suggest CGM wearables are evolving into infrastructure for the GLP-1 era, rather than one-off gadgets sold only through wellness apps.
AI-Powered Behavioral Coaching Becomes Standard in GLP-1 Wearables
As more people seek GLP-1 wearables to support weight loss, AI-powered behavioral coaching is becoming the standard feature, not an add-on. Signos is a clear example: its upcoming AI layer is designed to interpret continuous glucose monitor data moment by moment, turning raw numbers into specific prompts about meals, timing and activity. The system aims to build what the company calls metabolic self-knowledge by showing how small food swaps or schedule changes alter glucose curves. According to Signos, “The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data.” This philosophy aligns CGM weight loss tools with existing wearables, where the real value lies in daily nudges and simple experiments, rather than occasional lab-style readings.
Oura and Rivals Eye New Form Factors for the CGM Weight Loss Boom
The surge in GLP-1 prescriptions is shaping strategy across the broader wearable market, from rings to patches. Major players such as Oura are exploring how to position their devices as companions in the GLP-1 weight loss journey, even if they do not track glucose directly. In parallel, companies working with continuous glucose monitor hardware are seeking new form factors that feel more like everyday accessories and less like medical equipment. The goal is to make glucose monitoring and metabolic feedback as routine as step counts or sleep scores. As GLP-1 users look for tools to prevent rebound weight gain, these devices are racing to offer integrated views of glucose, activity, sleep and behavior. The result is a growing category of GLP-1 wearables built around lifestyle coaching and long-term maintenance, rather than short-term dieting.